Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma -- With Much Faster Treatment Time

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as reported by Dr. Saby George of Roswell Park Comprehensive Cancer Center today at the 2024...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news